Managing quality in clinical trials is the focus of daily activities that,

Size: px
Start display at page:

Download "Managing quality in clinical trials is the focus of daily activities that,"

Transcription

1 This article describes a targeted review of a quality management system that provides the organization with the inherent ability to identify, analyze, and address possible performance issues through the appropriate use of metrics. Liz Wool, RN, BSN, CCRA, CMT Intertwining Quality Systems with Metrics to Improve Trial Quality Managing quality in clinical trials is the focus of daily activities that, per the Clinical Trials Transformation Initiative (CTTI), substantiate the clinical research community s ability to effectively and efficiently answer the intended question about the benefits and risks of a medical product (therapeutic or diagnostic) or procedure while assuring protection of human subjects. 1 At the Drug Information Association s 2011 Annual Meeting, a presenter from the European Medicines Agency (EMA) provided a description of quality as sufficient to support the decision-making process on medicines throughout the clinical development and postmarketing authorization. 2 With the advent of increasing protocol complexities, technological capabilities, and globalization of research, a prospective, systematic, and methodical approach to ensuring quality in clinical trials is needed and is being advocated by regulators. Additionally, both the Food and Drug Administration (FDA) and EMA are collaborating with all stakeholders in clinical research to define and describe the elements of quality by design (QbD) in the context of clinical trial conduct. QbD incorporates the elements of a quality management system with benchmarks to the International Conference on Harmonization (ICH) in the ICH Q7 through Q10 documents and the International Organization for Standardization s ISO 9000 standards for quality management systems. In May 2012, the EMA hosted a workshop that focused on a reflection paper by the agency s Good Clinical Practice (GCP) International Working Group about risk-based quality management in clinical trials. The group requested input from various stakeholders (including ACRP) on what the QbD elements, context, and framework are for clinical trials. Similarly, the FDA and CTTI are launching the QbD workstream in As clinical researchers in the 21st century, stating that we have standard operating procedures (SOPs) and training is not defining a quality management system. This article describes a targeted review of a quality management system that, when adhered to in its entirety, provides the organization with steps for defining, planning, monitoring, measuring, and continuously improving the quality of its work, leading to the inherent ability to identify, analyze, and address possible performance issues through the appropriate use of metrics. Performance Metrics in Clinical trials Quality System Rather than focus solely on GCP compliance, SOPs, processes, forms, and training, there needs to be a renewed focus on building quality within an organization that inherently possesses the culture of quality. 3 A quality x 29

2 management system sets out the standards to be achieved and the method to meet them. The system should define what people, actions, and documents should be employed to conduct the work in a consistent manner, leaving evidence of what has happened. It may include manuals, handbooks, procedures, policies, records, and templates. 4 In 1946, the International Organization for Standardization (ISO) was founded, and in 1987, it published the first ISO 9000 standard for quality management systems. 5 Many people believe that ISO 9000 focuses only on manufacturing of products; however, ISO 9001:2008 was written such that small businesses (e.g., consulting firms) can implement ISO 9000 for their organizations. The ISO definition for quality states that the quality of something can be determined by comparing a set of inherent characteristics with a set of requirements. With this in mind, this article will discuss the quality management system principles espoused in ISO , extrapolating its use in the global clinical research arena. Additional terms that organizations may use to describe their quality management system include clinical quality system, integrated quality management, quality management, or total quality management. From a practical standpoint, it is important to understand how the elements and components of an organization s quality management system relate to this article s description of a quality management system in order to perform a comprehensive gap analysis. Due to space limitations, alternative theories and methods will not be discussed here. Kleppinger and Ball, in their article Building Quality into Clinical Trials with the Use of a Quality Systems Approach, describe the utility and application of ISO quality management systems principles for clinical trial planning, execution, ongoing monitoring, and continuous improvement during the clinical trial lifecycle. 6 The authors assert that, even though a quality system does not impose something totally new on clinical research, a systematic approach will produce a more reliable and useful end product that is, high- quality data obtained without compromising the protection of human subjects rights and welfare. After implementing a quality management system, assessing, monitoring, and measuring how well the organization is performing to the established standards and methods is required. Using visual inspection and confirmation, document review, data analytics and review, and metrics, the organization implements the foundational cornerstones for assessing its performance. Elements of a Quality System The overarching framework for a quality management system is illustrated in Figure 1, which visualizes the critical plan, do, check, act approach of a committed organization to quality through the development, implementation, and maintenance of a quality management system. Figure 1 Framework for a Quality System Responsibility, Review of QMS Issue Escalation Metrics System Corrective and Preventive Action Program Performance Dashboards GCP Quality Assurance Unit, Annual Audit Plan Risk Quality System (QMS) Framework Process Improvement A quality management system provides the prospective, systematic, methodical, scientifically based framework to plan, manage, monitor, and measure the quality of the organization and its performance throughout the clinical trial and product development lifecycles. Specifically, the quality management system establishes the standards under which work will be performed and how the organization and personnel perform and document their assigned clinical trial activities, duties, and functions. An additional illustration is noted in Figure 2, which outlines the phases of product development for clinical research benchmarking to similar illustrations for the ICH Q10 Pharmaceutical Quality System Guideline. 7 This network system of interrelated processes provides uniformity and consistency for people and actions, describing the work performed and how the work is documented, as outlined in Figure 3. In the clinical trials context, this Quality Policy, Quality Manual Deviation Procedural Documents, Document Control Process Monitoring and Analyses Change Control Training 30 x Monitor August 2012

3 framework establishes a reliable network of commitments throughout the organization and business enterprise, which each employee of and contributor to the research site knows and understands and to which everyone performs. Thereby, the organization or business establishes, maintains, and manages this network of commitments, which supports building quality into the clinical trial practices. 8 Figure 2 An Outline of Clinical Research Phases Within a Quality System (QMS) Structure Protocol Design & Operational Design Investigational Product-Device Planning GCP Quality System Building Quality Into the Clinical Program Start-Up Conduct Close-Out Good Clinical Practices Data Lock & Analysis, CSR* Marketing Application A quality management systems approach in clinical research is a further extension of delivering quality care for those patients who volunteer to participate in clinical research. QMS Elements Enabler Enabler Responsibilities Quality Culture, Policy, Objectives Resources Quality Commitment: All Staff Process Performance Systems, Processes, Documentation Quality-Performance Monitoring System (Quality Control/Quality Assurance) Corrective & Preventive Action (CAPA) System Change System-CQI, Document Control Review: Ongoing Acceptability of the System Knowledge Risk Inherent in a quality management system is documenting the work performed, evaluating deviations from the established quality standards and controls, and taking the necessary actions for immediate and continuous process improvement. This framework for quality is not so different from that used in hospitals and medical institutions, which must obtain and maintain accreditation of their facility, per country/state requirements. Therefore, a quality management systems approach in clinical research is a further extension of delivering quality care for those patients who volunteer to participate in clinical research. Table 1 presents a targeted description and application (examples) of critical aspects of both the quality management system framework and the plan, do, check, act principles. *CSR=clinical study report. execution of the clinical trial to the established quality standards. Specifically, quality metrics provide the ability to measure progress to the standards and goals defined by the organization. Quality metrics are reported as the error rate, and require predefined tolerance limits for effective monitoring, measurement, and reporting of quality and compliance signals to the organization. Note that what most organizations refer to as key quality indicators are a subset of performance indicators. For example, a site monitoring report may be completed on time; however, is the report completed Figure 3 The Network of Interrelated Processes correctly per the standards outlined in the monitoring visit report completion guidelines, monitoring visit report template, monitoring plan, and monitoring SOP? Did the CRA/monitor capture critical issues, protocol deviations, or violations in the monitoring report as identified by either database review of deviation listings or during an onsite quality assessment visit that was performed by his or her supervisor or the sponsor? Additional examples are described in Table 2. Upon identification of a metric that has either met or is out of range of the predetermined tolerance limits, the next Metrics: Reporting Performance of the Quality System When defined and used appropriately, metrics are an effective tool for monitoring and measuring the performance of an organization s quality system and People Network of interrelated processes with each process made up of: Work Activities, Tasks Records, Documents, Forms Resources, Rules, Regulations Reports, Materials Supplies, Tools, Equipment x 31

4 Table 1 Descriptions and Examples of Quality System Elements Quality System Element Quality Culture An organizational value system that results in an environment that is conducive to the establishment and continual improvement of quality Maintain an awareness of quality as a key cultural issue Make sure that there is plenty of evidence of management s leadership Empower employees and encourage self-development and self-initiative Recognize and reward the behaviors that tend to nurture and maintain quality culture Commitment Required to establish authority and commitment to the provision of resources to develop, maintain, and sustain the quality system Quality Policy Describes how an organization approaches quality and the requirements for meeting expectations. Risk Supportive framework (enabler) for the quality management system A continuous, formal process involving the systematic application of documented management policies, procedures, and practices to the tasks of analyzing, evaluating, controlling, and communicating risk Knowledge Supportive framework (enabler) for the quality management system Prospective, controlled, and methodical approach for identifying/capturing and disseminating collective organizational expertise (past, present) for staff to perform their roles, duties, activities, and functions in clinical research to improve organizational performance The process usually involves several of the following stages or subprocesses in the use of knowledge: create, identify, collect, organize, share, adapt, and use 9 Communication A quality system s requirements, standards, and effectiveness need to be communicated to everyone involved in a particular activity in order for the system to work 32 x Monitor August 2012 Example Incorporated into mission statement, employee on-boarding training program, and employee handbook Executed at a division/department level in a manner that provides a direct, concrete, and succinct link between quality and the specialty areas of employees Quality policy document for the organization/business that is referred to and adhered to by the organization at all levels Video on organization/business intranet communicating this commitment to all employees Assignment of resources (people, funds, facilities, equipment) as required to develop, maintain, and continuously manage the quality system Guy s and St. Thomas National Health Service (NHS) Foundation Trust Quality Policy The Quality Policy describes the quality system that is required to ensure that clinical research conducted in NHS clinical research facilities in the U.K. fulfills statutory requirements laid down in current and any future regulations, as well as research governance guidelines. The aim of the policy is to maintain a quality management process that not only meets the requirements of applicable regulations and guidelines, but also adds value to the reputation of the trust as a location where high-quality, robust research is conducted. Risk management principles may be applied to clinical trials by prospectively identifying those aspects that are critical to ensure the reliability of results (data quality, data integrity) and protection of study subjects Protocol Risk Plan for global clinical trial execution Recruitment Plan risk assessment and associated Risk Plan to ensure on-time subject enrollment Conduct lessons learned during the clinical trial and review and identify information that is important to other teams to improve performance in their job, on their protocol; includes real-time analysis and review of systems, processes, SOPs, and methods and implementation of changes in a timely manner with rapid communication to staff ACRP s Online Community, which includes sharing of best practices, lessons learned, SOPs; the end-user reviews the information and utilizes it as stated or modifies it for use (e.g., site SOPs and forms posted) Policies, procedures, study requirements, and responsibilities should be communicated prospectively to affected staff, contract research organization (CRO) and service provider personnel, and clinical investigators; adequate training should be provided to all study staff, per their job functions (sites, sponsors, CROs, vendors, contractors, consultants) (continues)

5 Table 1 Descriptions and Examples of Quality System Elements (continued) Quality System Element Job Responsibilities and Assessment of Personnel Competencies Job descriptions are present and current, and there is a methodology for continuously reviewing and updating them according to changes in the regulatory landscape and other job responsibilities Do personnel possess competencies, knowledge, experience, skills, and training to execute their assigned responsibilities, duties, functions, and activities? Document Control Document control is a consistent method of controlling documents that includes version numbering, dating, issuing, and withdrawing as controlled procedures Ensures that only the current version of the procedural document is used by all personnel Quality Plans Documents specifying which procedures and associated resources shall be applied, by whom, and when to a specific project, product, process, or contract; describes how the quality system is applied to a specific deliverable Quality Standards Organizational standards/requirements for conducting business Regulations, guidances, guidelines, regulatory authority inspection manuals Quality Control A set of activities intended to ensure that quality requirements are actually being met Monitoring and Measurement of the Quality System Organization monitors customers perceptions of whether it has met their requirements Suitable methods are utilized to monitor and measure the organization s performance Facilities and Equipment Controlled environments required to execute the protocol Quality Assurance The aspect of quality management that focuses on the confidence that quality requirements are fulfilled Self-inspection audits of the quality system, processes, activities, and documents to independently assure that the defined requirements/standards for the protocol/system/ process/procedure have been adhered to Conducted by defined, qualified personnel independent of the activity; performed in a systematic manner Example Each position has a current and documented job description, employee/contractor training plan, and training file Procedural documents include SOPs, informed consent templates, and investigational product accountability logs, etc. Protocol-Specific Quality Plan Monitoring Plan, Data Plan, Project Plan, Recruitment Plan, Quality Oversight Plan of Third Parties Plan, Data Monitoring Committee Charter, Data-Safety Monitoring Plan, Annual Audit Plan Protocol-specific requirements for endpoint assessments (i.e., by an MD or certified assessor), and other study-related procedures/ activities Each informed consent is obtained prior to any study-specific procedures performed on the subject Protocol (e.g., subject enrollment criteria) Trial-specific procedures and expectations (e.g., correct data entry per the source documentation into electronic data capture) Predefined requirements (e.g., temperature at which investigational product must be stored) Organizational controlled, procedural documents (e.g., SOPs [unblinding, randomization], templates, forms, job aids [flow charts, reference cards, business operations manuals]) Procedural documents include: SOPs, informed consent templates, investigational product accountability logs Sponsor s clinical research associate (CRA)/monitor perform onsite monitoring visits to a clinical investigator Refrigerator and freezer temperature is routinely checked/monitored to ensure the temperature is within specified limits (requirements); this routine check/monitoring is documented in the temperature log Data analyses of performance (predefined/predetermined metrics and tolerance limits) Customer report of product quality complaints Internal audits of the quality system (see quality assurance section) Clinical site s refrigerators/freezers possess the protocolrequired temperature range with documented evidence of ongoing monitoring, calibration, and maintenance per manufacturer specifications Organization s routine audit of the quality system Clinical study report audit Clinical investigator site audit Quality systems audit of vendor/third party Trial Master File audit (continues) x 33

6 Table 1 Descriptions and Examples of Quality System Elements (continued) Quality System Element Example Deviation Protocol deviation log maintained by the site and by CRAs/ Supports learning in the organization through the identification, monitors recording, and investigation of activities that are not performed correctly or as planned, and provides the framework on how to investigate, plan, and change the way activities are performed Corrective and Preventive Action (CAPA) Program Incorrect version of the informed consent used for a study Corrective action aims to address and manage identified areas subject (corrective action: current version of consent in the file) of noncompliance and nonconformity (an issue or problem) by Subject s investigational product dose not adjusted per the investigating the root cause in order to accurately eliminate it results of their liver or renal values, as required by the protocol Preventive actions aim to establish proactive methods/steps/ (preventive action: checklist, per patient visit, outlining actions to foresee any issues and to prevent them from occurring requirements) Continuous Improvement Use of audit findings, audit conclusions, analysis of data, The organization shall continually improve the effectiveness management reviews, and deviation management to improve the of the quality system through the use of the quality policy, quality system/organization quality objectives, audit results, analysis of data, CAPA CAPA plans implemented as a result of audit conclusions, audit program, and management review findings, internal monitoring of systems/processes and quality Build on the knowledge known and learned to make system by staff, CRA/site monitor feedback proactive improvements in individual trials and across all trials, and in the business enterprise (close correlation to knowledge management for the organization) Issue Escalation Cases of suspected scientific/ethical misconduct and/or The issue escalation process describes how the project fraud are escalated within 24 hours to the compliance/quality identifies, tracks, and manages issues and action items that assurance department and senior management for investigation are generated throughout the project life cycle; it also defines how to escalate an issue to a higher level of management for resolution and how resolutions are documented Unanticipated issues and action items are assigned to a specific person for action and are tracked to resolution Review of the Quality System s Performance Biannual meeting and review of the quality system utilizing Senior management s overarching responsibility for review metric reports and performance dashboards and analysis, at predetermined intervals, of the functioning/ adequacy of the quality system utilizing key indicators of performance, quality, and revenue Has the quality system provided management with the information to reassure them of compliance to the organization s quality system? Through the assessment of metrics (performance, quality indicators), does the organization need to add anything or change anything in the quality system to meet organizational quality objectives? step is the evaluation of the metric and any relevant companion metrics. This analysis supports a robust and comprehensive root cause analysis as to what the issue is, the issue s impact, and what corresponding directed and focused CAPA steps and continuous improvement measures should be taken. Further, metrics need to be evaluated with the associated risk management plan and actions analyzed: Did our mitigation plans work? Should we implement our predefined contingency plans? Do we need to reevaluate the assumptions reference in the development of the risk management plan and revise that plan accordingly? Is this an issue we did not expect, thereby necessitating the need for the development of a new risk management plan? Quality systems metrics analysis focuses on the following critical questions: How is the system performing? 2. Which aspects of the system are performing poorly or need improvement? 3. Which aspects of the system are performing adequately? 4. What is ideal performance? 5. Are the improvements having the desired effect? Figure 4 presents some useful guidelines for successfully using and evaluating quality systems metrics. 10 Summary Effective execution of clinical trials featuring quality built within requires 34 x Monitor August 2012

7 Table 2 Examples of How Quality Indicators are Subsets of Performance Indicators Performance Indicator Quality Indicator Case report forms (CRFs) completed and CRF query rate < 5% submitted on time > 90% Imaging study completed on time >95% Image readability > 98% Blood samples collected on time > 95% Quantity not sufficient < 1% Staff trained on SOPs prior to performing SOP deviation rate < 3% responsibilities/tasks in SOP > 95% Staff trained to the protocol-investigational Protocol deviations-violations < 2% plan prior to performing delegated study tasks > 95% Site staff delegated tasks prior to study-start > 95% Subjects enrolled on time > 85% Informed consent obtained 100% Informed consent obtained 100% a prospective, systematic approach to quality through the implementation of a robust and comprehensive quality management system whereby metrics provide the ability to measure an organization s performance. The qual- Staff delegated responsibilities correctly per licensure and/or certification requirements per state/country 100% Subjects enrolled meet enrollment criteria 100% Subjects consented with the correct ICF version 100% Subjects consented prior to study-specific procedures 100% ity management system principles described in this article represent the framework and components of progressive 21st century practices for use by all stakeholders in the clinical research enterprise. Figure 4 Guidelines for Using and Evaluating Quality Systems Metrics Successfully Using Quality Systems Metrics Identify the stakeholders and the metrics for their activities Determine the metrics required for periodic management review of the quality system Determine how the metrics will change the way you perform your business Select the right metrics and rationalize the calculation rules (do you have this requisite expertise inhouse?) Determine how you will use the results Define the reporting mechanisms (scorecard, dashboard, real-time reports) and issue escalation pathways both internally and externally with other parties Determine the right source of the data Collect the data and validate the results Continuously evaluate the metrics (obtain feedback and study the utility of your measurement) Continuously improve the process Communicate the results Successfully Evaluating Quality Systems Metrics What does this metric measurement mean? What will I do with this information? How will this communicate a quality performance threshold or tolerance limit requiring investigation or evaluation? Do I need another metric to get the whole picture? Identify any companion metrics to assist with the evaluation References 1. Clinical Trials Transformation Initiative. Available at tion.org/scope. 2. Sweeney F Defining Quality in Clinical Trials. DIA Annual Meeting, Cameron K, Since W A framework for organizational quality culture. Quality Journal, 1999, pp BARQA Quality Systems Workbook. Available at (free download available). 5. International Organization for Standardization; 6. Kleppinger C, Ball L Building quality into clinical trials with use of a quality systems approach. Clinical Infectious Disease Journal 51(Supp. 1): S111-S ICH Q10 Pharmaceutical Quality System presentation, /quality/quality-single/article/pharmaceutical -quality-system.html. 8. Burrow D. CDER BIMO Warning Letters as Case Studies-Building Quality in Clinical Trials. Presentation, ACRP Global Conference, American Productivity and Quality Center Publication Stages of Implementation: A Guide for Your Journey to Knowledge Best Practices. Houston, Texas. 10. Zuckerman D Pharmaceutical R & D Metrics. Gower Publishing Ltd., England. Additional Sources Cianfrani C, Tsikais J, West J ISO 9001: 2008, Explained. Milwaukee, Wis.: ASQ Quality Press. Clinical Trials Transformation Initiative. Developing Effective Quality Systems in Clinical Trials: An Enlightened Approach; ISO 9001:2008. Quality Systems Requirements; Ribière V, Khorramshahgol R Integrating total quality management and knowledge management. Journal of Systems 16(1). Toth-Allen J Building Quality into Clinical Trials: An FDA Perspective. FDA Webinar, 04 May Tricker R ISO 9001:2008 for Small Businesses. Burlington, Mass.: Elsevier. Liz Wool, RN, BSN, CCRA, CMT, has 22 years of experience in the clinical research industry. She is president and CEO of QD-Quality and Training Solutions, Inc. (QD-QTS), a clinical quality systems, training, auditing, and CRO-vendor oversight consulting firm providing services to institutions, investigators, sponsors, and CROs. QD-QTS has offices in San Bruno, Calif., and Franklin, Tenn. A certified Master Trainer and instructional designer, she is also a member of ACRP s Association Board of Trustees and Editorial Advisory Board. She can be reached at lizwool@qd-qts.com. x 35

BUILDING QUALITY INTO CLINICAL TRIALS AN FDA PERSPECTIVE

BUILDING QUALITY INTO CLINICAL TRIALS AN FDA PERSPECTIVE BUILDING QUALITY INTO CLINICAL TRIALS AN FDA PERSPECTIVE Jean Toth-Allen, Ph.D. Biophysicist Office of Good Clinical Practice Office of the Commissioner May 14, 2012 1 Overview I. Background why we are

More information

CLINICAL DATA MONITORING PLAN (CDMoP) PROTOCOL # [0000] [TITLE]

CLINICAL DATA MONITORING PLAN (CDMoP) PROTOCOL # [0000] [TITLE] CLINICAL DATA MONITORING PLAN (CDMoP) PROTOCOL # [0000] [TITLE] CONTRACT RESEARCH ORGANIZATION SPONSOR [NAME] [ADDRESS] 1 TABLE OF CONTENTS 1. Purpose 3 2. References 3 3. Study Roles and Responsibilities

More information

Barnett International and CHI's Inaugural Clinical Trial Oversight Summit June 4-7, 2012 Omni Parker House Boston, MA

Barnett International and CHI's Inaugural Clinical Trial Oversight Summit June 4-7, 2012 Omni Parker House Boston, MA Barnett International and CHI's Inaugural Clinical Trial Oversight Summit June 4-7, 2012 Omni Parker House Boston, MA This presentation is the property of DynPort Vaccine Company LLC, a CSC company, and

More information

through advances in risk-based

through advances in risk-based Insight brief Quintiles is a market leader with >100 risk-based monitoring studies Quintiles developed solutions that bring as much as 25% cost reduction over traditional trial execution approaches Transform

More information

U.S. Food and Drug Administration

U.S. Food and Drug Administration U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained

More information

1 www.imarcresearch.com

1 www.imarcresearch.com Risk Management in Clinical Research: PROCESS DEVELOPMENT & APPLICATION Introduction Recently, two key pieces of guidance were released from Food and Drug Administration (FDA) and European Medicines Agency

More information

Guidance for Industry. Q10 Pharmaceutical Quality System

Guidance for Industry. Q10 Pharmaceutical Quality System Guidance for Industry Q10 Pharmaceutical Quality System U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation

More information

Contents. Project Management: August 2005 Page 2 Clinical Research Operational Standards for Professional Practice for Professional Practice

Contents. Project Management: August 2005 Page 2 Clinical Research Operational Standards for Professional Practice for Professional Practice Project Management: August 2005 Contents Introduction........................................................... 4 About this standard: what is the importance of project management?................. 4

More information

Workshop on Quality Risk Management Making Trials Fit for Purpose

Workshop on Quality Risk Management Making Trials Fit for Purpose Clinical Trials Transformation Initiative Workshop on Quality Risk Management Making Trials Fit for Purpose Andy Lee SVP, Global Clinical Operations, Genzyme Corporation August 23/24, 2011 Hyatt Regency,

More information

QUALITY CONTROL AND QUALITY ASSURANCE IN CLINICAL RESEARCH

QUALITY CONTROL AND QUALITY ASSURANCE IN CLINICAL RESEARCH QUALITY CONTROL AND QUALITY ASSURANCE IN CLINICAL RESEARCH Martin Valania, Executive Director, Corporate QA and Compliance Introduction Pharmaceutical companies recognize the benefits of carefully managing

More information

Marie-Claire Rickard, GCP & Governance Manager Rachel Fay, GCP & Governance Manager Elizabeth Clough, R&D Operations Manager

Marie-Claire Rickard, GCP & Governance Manager Rachel Fay, GCP & Governance Manager Elizabeth Clough, R&D Operations Manager Standard Operating Procedures (SOP) for: Monitoring SOP 28 Version 7.0 Number: Number: Effective Date: 29 th November 2015 Review Date: 6 th January 2017 Author: Reviewer: Reviewer: Authorisation: Name

More information

Introduction. The Evolution of the Data Management Role: The Clinical Data Liaison

Introduction. The Evolution of the Data Management Role: The Clinical Data Liaison Introduction The CDL is a new role that will become a standard in the industry for companies that want to make more efficient use of limited resources: time and money. A CDL is key in that he or she conducts

More information

DAIDS Bethesda, MD USA. POLICY Requirements for Clinical Quality Management Plans

DAIDS Bethesda, MD USA. POLICY Requirements for Clinical Quality Management Plans CHANGE SUMMARY: This policy and associated appendices have been reviewed for accuracy and updated to meet 508 compliance guidelines. Key changes to the policy require all sites to submit a bi-annual Clinical

More information

What We Are..! www.ardent-cro.com

What We Are..! www.ardent-cro.com Your Trusted CRO! Regus, Level-2, Connaught Place, Bund Garden Road, Pune-411001, MH, India. Phone: 020-65-31-31-71 Email: ardent@ardent-cro.com Web: What We Are..! Ardent Clinical Research Services is

More information

ICH CRA Certification Guide March 2009

ICH CRA Certification Guide March 2009 ICH CRA Certification Guide March 2009 ICH CRA CERTIFICATION GUIDE... 1 GENERAL INFORMATION... 2 BENEFITS OF CERTIFICATION... 2 INDUSTRY RECOGNITION... 2 ABOUT THE EXAM... 2 CRA DEFINITION... 2 REQUIREMENTS

More information

Guidance for Industry Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects

Guidance for Industry Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects Guidance for Industry Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects U.S. Department of Health and Human Services Food and Drug Administration Center for Drug

More information

CDC UNIFIED PROCESS PRACTICES GUIDE

CDC UNIFIED PROCESS PRACTICES GUIDE Document Purpose The purpose of this document is to provide guidance on the practice of Quality Management and to describe the practice overview, requirements, best practices, activities, and key terms

More information

Innovative Solutions Designed to Improve Operational Capacity, Efficiency and Effectiveness in Clinical Monitoring

Innovative Solutions Designed to Improve Operational Capacity, Efficiency and Effectiveness in Clinical Monitoring Innovative Solutions Designed to Improve Operational Capacity, Efficiency and Effectiveness in Clinical Monitoring Brett Barber, Sr. Director, Strategic Resourcing Nicole Baker, Sr. Director, Strategic

More information

PHARMACEUTICAL QUALITY SYSTEM Q10

PHARMACEUTICAL QUALITY SYSTEM Q10 INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL QUALITY SYSTEM Q10 Current Step

More information

Aligning Quality Management Processes to Compliance Goals

Aligning Quality Management Processes to Compliance Goals Aligning Quality Management Processes to Compliance Goals MetricStream.com Smart Consulting Group Joint Webinar February 23 rd 2012 Nigel J. Smart, Ph.D. Smart Consulting Group 20 E. Market Street West

More information

EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART

EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART Framework Labs generate data that are used to make decisions on the safety and efficacy of medicinal products; consequently,

More information

To Certify or Not to Certify

To Certify or Not to Certify To Certify or Not to Certify Sandra Halvorson, BA, CCRP Clinical Research Coordinator II CIBMTR Minneapolis Campus Sue Logan, BS, CCRP Clinical Research Coordinator II CIBMTR Minneapolis Campus November

More information

To Certify or Not to Certify Sandra Halvorson, BA, CCRP

To Certify or Not to Certify Sandra Halvorson, BA, CCRP To Certify or Not to Certify Sandra Halvorson, BA, CCRP Clinical Research Coordinator II CIBMTR Minneapolis Campus Sue Logan, BS, CCRP Clinical Research Coordinator II We have no financial relationships

More information

Clinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity

Clinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity Clinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity Michelle Quaye Regulatory Manager, Advanced Therapy Trials University College London Overview The Principles of Good

More information

Why Monitoring Is More Than Just SDV

Why Monitoring Is More Than Just SDV Why Monitoring Is More Than Just SDV Medidata and other marks used herein are trademarks of Medidata Solutions, Inc. All other trademarks are the property of their respective owners. Copyright 2013 Medidata

More information

Guidance for Industry Quality Systems Approach to Pharmaceutical CGMP Regulations

Guidance for Industry Quality Systems Approach to Pharmaceutical CGMP Regulations Guidance for Industry Quality Systems Approach to Pharmaceutical CGMP Regulations U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

More information

Welcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to

Welcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to Welcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to introduce you to the concepts behind risk-based monitoring,

More information

Sharon H. Johnson, BS, MS 123 Main Street Capital City, VA 00000 Phone: 434-555-1234 Email: shjohnson@email.com

Sharon H. Johnson, BS, MS 123 Main Street Capital City, VA 00000 Phone: 434-555-1234 Email: shjohnson@email.com SAMPLE CRA CV Sharon H. Johnson, BS, MS 123 Main Street Capital City, VA 00000 Phone: 434-555-1234 Email: shjohnson@email.com Education: Masters of Science, Healthcare Administration, Capital City University,

More information

No. 706. Page 1 of 5. Issue Date 4/21/2014

No. 706. Page 1 of 5. Issue Date 4/21/2014 Subject: ROUTINE MONITORING VISITS Standard Operating Procedure Prepared By: Beaumont Research Coordinating Center, Research Institute PURPOSE Prior Issue Date 8/15/2011 No. 706 Issue Date 4/21/2014 Page

More information

Infoset builds software and services to advantage business operations and improve patient s life

Infoset builds software and services to advantage business operations and improve patient s life Infoset builds software and services to advantage business operations and improve patient s life Clinical Data Management ecrf & EDC Patient Support Programs Medication Adherence Mobile e-health Big Data

More information

Pharmaceutical Quality & Clinical Research Quality: The Interaction

Pharmaceutical Quality & Clinical Research Quality: The Interaction 4 th Jerusalem Conference: Quality by Design (QbD)) & Pharma Sciences, May 20-22, 2014 The Edmund Safra Campus, The Hebrew University of Jerusalem Pharmaceutical Quality & Clinical Research Quality: The

More information

Model Approach for Risk-Based Monitoring

Model Approach for Risk-Based Monitoring Model Approach for Risk-Based Monitoring September 2013 Legal Disclaimer... 3 TransCelerate Risk-Based Monitoring Course... 5 Module 1 Introduction to Risk-Based Monitoring (RBM)... 7 Objective 1 Describe

More information

Metrics 101. Produced by the TMF Reference Model Metrics and Reporting Sub-team. 1 August 2014

Metrics 101. Produced by the TMF Reference Model Metrics and Reporting Sub-team. 1 August 2014 Metrics 101 Produced by the TMF Reference Model Metrics and Reporting Sub-team 1 August 2014 Agenda Why a metrics program? Goals of a metrics program Types of metrics Further analytics on metrics Metrics

More information

Quality Management in Clinical Trials

Quality Management in Clinical Trials CLINICAL CASE STUDY SERIES Quality Management in Clinical Trials Clinical trials are conducted to collect the data necessary to provide information for academia, industry, and regulators to make decisions

More information

Objectives. The Paper Tells the Story

Objectives. The Paper Tells the Story Notes to File: An Auditor s Perspective Lorrie D. Divers, CCRP, RQAP-GCP Executive Director, Global Quality Assurance & Compliance ACM Medical Laboratory / ACM Global Central Laboratory Clinical Translation

More information

The role, duties and responsibilities of clinical trials personnel Monitoring: rules and recommendations

The role, duties and responsibilities of clinical trials personnel Monitoring: rules and recommendations The role, duties and responsibilities of clinical trials personnel Monitoring: rules and recommendations Maria Luisa Paoloni OPBG Clinical & Research Services Monitoring and Responsible of monitoring:

More information

Clinical Investigator Training Course

Clinical Investigator Training Course Clinical Investigator Training Course Investigator Responsibilities in Biomedical Research Covered by FDA Regulations Lisa Zimmerman Objectives Discuss Clinical Investigator Obligations according to FDA

More information

Quality in pharmacovigilance systems

Quality in pharmacovigilance systems Quality in pharmacovigilance systems June 20 th, 2014 Lisa Stagi, Medical Compliance Leader Roche Spa Quality systems in pharmacovigilance: legal requirements Regulation 1235/2010 e Directive 2010/84 Legal

More information

ICH guideline Q10 on pharmaceutical quality system

ICH guideline Q10 on pharmaceutical quality system September 2015 EMA/CHMP/ICH/214732/2007 Committee for Human Medicinal Products Step 5 Transmission to CHMP May 2007 Transmission to interested parties May 2007 Deadline for comments November 2007 Final

More information

Optimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy

Optimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy Optimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy Global Pharma Sourcing Conference December 6-7, 2011 Philadelphia, USA Nigel J. Smart, Ph.D. Smart Consulting

More information

Establish Collaborative Strategies to Better Manage a Global Vendor Network Devise a Proper Float Plan

Establish Collaborative Strategies to Better Manage a Global Vendor Network Devise a Proper Float Plan Establish Collaborative Strategies to Better Manage a Global Vendor Network Devise a Proper Float Plan CBI s Biopharmaceutical Forum on Clinical and Commercial Global Supply Chain Excellence Sandy Onorato

More information

Monitoring is considered a quality control (QC) process (ongoing activities

Monitoring is considered a quality control (QC) process (ongoing activities Peer Reviewed Describing a drug development program initiated using a quality-by-design approach, with special attention paid to assuring proactive quality planning at all stages of development. Jules

More information

IMP management at site. Dmitry Semenyuta

IMP management at site. Dmitry Semenyuta IMP management at site Dmitry Semenyuta TOP 5 FDA inspections finding 1999-2009 Center of Drug Evaluation and Research (CDER) Failure to follow the protocol Failure to keep adequate and accurate records

More information

The Role of the CRO in Effective Risk-Based Monitoring

The Role of the CRO in Effective Risk-Based Monitoring New Whitepaper The Role of the CRO in Effective Risk-Based Monitoring The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging

More information

Addressing Risk in Partner / Contractor Selection and Onboarding. Michael Davidson VP Quality Systems and Compliance March 2014

Addressing Risk in Partner / Contractor Selection and Onboarding. Michael Davidson VP Quality Systems and Compliance March 2014 Addressing Risk in Partner / Contractor Selection and Onboarding Michael Davidson VP Quality Systems and Compliance March 2014 Industry Trends Pfizer Overview Pfizer s Approach Risk Based Robust Due Diligence

More information

ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS

ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS STANDARD OPERATING PROCEDURE NO SOP 09 DATE RATIFIED 4/7/13 NEXT REVIEW DATE 4/7/14 POLICY STATEMENT/KEY OBJECTIVES:

More information

Needs, Providing Solutions

Needs, Providing Solutions Identifying Needs, Providing Solutions 1 I n d u s t r y The growth of medical research and the countless innovations coming from the pharmaceutical, biotechnology and medical device industry, has improved

More information

The Regulatory Binder/Trial Master File: Essential Records for the Conduct of a Clinical Trial

The Regulatory Binder/Trial Master File: Essential Records for the Conduct of a Clinical Trial The Regulatory Binder/Trial Master File: Essential Records for the Conduct of a Clinical Trial Clinical Research Operations & Regulatory Support (CRORS) Ann Glasse, RN, BSN, MBA Director-CRORS Objectives

More information

Standard 1. Governance for Safety and Quality in Health Service Organisations. Safety and Quality Improvement Guide

Standard 1. Governance for Safety and Quality in Health Service Organisations. Safety and Quality Improvement Guide Standard 1 Governance for Safety and Quality in Health Service Organisations Safety and Quality Improvement Guide 1 1 1October 1 2012 ISBN: Print: 978-1-921983-27-6 Electronic: 978-1-921983-28-3 Suggested

More information

Risk based monitoring using integrated clinical development platform

Risk based monitoring using integrated clinical development platform Risk based monitoring using integrated clinical development platform Authors Sita Rama Swamy Peddiboyina Dr. Shailesh Vijay Joshi 1 Abstract Post FDA s final guidance on Risk Based Monitoring, Industry

More information

INSERT COMPANY LOGO HERE BEST PRACTICES RESEARCH

INSERT COMPANY LOGO HERE BEST PRACTICES RESEARCH INSERT COMPANY LOGO HERE BEST PRACTICES RESEARCH Background and Company Performance Industry Challenges esource: Electronic Clinical Trial Solution Clinical trial sponsors and clinical research organizations

More information

Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute

Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute Understand the protocol completely Recognize institutional polices

More information

Remote Monitoring of Clinical Trials and EMRs

Remote Monitoring of Clinical Trials and EMRs Remote Monitoring of Clinical Trials and EMRs Sandra SAM Sather, MS, BSN, CCRA, CCRC Vice-President Clinical Pathways LLC samsather@clinicalpathwaysresearch.com Lindsey Spangler, J.D. Associate Director,

More information

An information platform that delivers clinical studies better, faster, safer and more cost effectively

An information platform that delivers clinical studies better, faster, safer and more cost effectively An information platform that delivers clinical studies better, faster, safer and more cost effectively Powering Process & Performance Proactively manage study start-up and execution Risk profile new sites

More information

Good Documentation Practices

Good Documentation Practices Good Documentation Practices Clinical Research Operations & Regulatory Support Ann Glasse, RN, BSN, MBA Director, Regulatory Support Author: Johanna Stamates, RN, MA, CCRC, CHRC Objectives Recognize the

More information

Study Start-Up SS-204.01. STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV)

Study Start-Up SS-204.01. STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV) Study Start-Up SS-204.01 STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV) Approval: Nancy Paris, MS, FACHE President and CEO 08 March 2012 (Signature and Date) Approval: Frederick M. Schnell,

More information

Clinical Training Management

Clinical Training Management Clinical Training Management Learning and Compliance for Clinical Research Helping to Fuel the Growth of CROs and Service Providers According to clinical researcher CenterWatch, the FDA and global regulatory

More information

Position Paper: Risk-Based Monitoring Methodology

Position Paper: Risk-Based Monitoring Methodology Position Paper: Risk-Based Monitoring Methodology 1. Abstract Current On-site Monitoring practices are frequency-based, conform to a prescribed monitoring visit schedule, and provide generalized quality

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Oversight of Clinical Investigations A Risk-Based Approach to Monitoring U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research

More information

CNE Disclosures. To change this title, go to Notes Master

CNE Disclosures. To change this title, go to Notes Master CNE Disclosures Successful Completion: Participants must complete an evaluation form to receive a certificate of completion Contact Hours: 1 contact hour is available to those who meet the successful completion

More information

The Monitoring Visit. Denise Owensby, CCRP Sr. Clinical Research Coordinator Clinical & Translational Science Center University of California, Davis

The Monitoring Visit. Denise Owensby, CCRP Sr. Clinical Research Coordinator Clinical & Translational Science Center University of California, Davis The Monitoring Visit Denise Owensby, CCRP Sr. Clinical Research Coordinator Clinical & Translational Science Center University of California, Davis Disclosure The information herein is not intended to

More information

Catherine Jahrsdorfer, RN, BSN Director of Clinical Services USF Health Office of Clinical Research

Catherine Jahrsdorfer, RN, BSN Director of Clinical Services USF Health Office of Clinical Research A Practical Guide on Applying USF HRPP P&Ps in the Clinical Setting Catherine Jahrsdorfer, RN, BSN Director of Clinical Services USF Health Office of Clinical Research Learning Objectives Recognize the

More information

The Study Site Master File and Essential Documents

The Study Site Master File and Essential Documents The Study Site Master File and Essential Documents Standard Operating Procedure Office of Health and Medical Research Queensland Health SOP reference: 002 Version number: 1 Effective date: 01 June 2010

More information

LIBRARY GUIDE: Clinical Medical Device

LIBRARY GUIDE: Clinical Medical Device LIBRARY GUIDE: Clinical Medical Device Table of Contents Overview... 3 Clinical Curriculum Core Program Course Descriptions: A Tour of Health Canada (PHDV89)...5 A Tour of Health Europe (PHDV90)...5 A

More information

Execution in Clinical Research

Execution in Clinical Research TM TM Execution in Clinical Research Unrivaled CRA training program drives success for Sponsors. Sponsors have many choices in choosing development partners at the CRO level. The need for a documented

More information

POLICY AND PROCEDURES OFFICE OF STRATEGIC PROGRAMS. CDER Master Data Management. Table of Contents

POLICY AND PROCEDURES OFFICE OF STRATEGIC PROGRAMS. CDER Master Data Management. Table of Contents POLICY AND PROCEDURES OFFICE OF STRATEGIC PROGRAMS CDER Master Data Management Table of Contents PURPOSE...1 BACKGROUND...1 POLICIES...2 RESPONSIBILITIES...2 PROCEDURES...4 REFERENCES...5 DEFINITIONS...5

More information

Empowering the Quality and Regulatory Compliance Functions

Empowering the Quality and Regulatory Compliance Functions Empowering the Quality and Regulatory Compliance Functions Management must take steps to ensure that regulatory and quality compliance is everyone s responsibility. By: J. Glenn George, Kenneth Imler,

More information

The Concept of Quality in Clinical Research. Dorota Śwituła Senior Clinical Quality Assurance Advisor

The Concept of Quality in Clinical Research. Dorota Śwituła Senior Clinical Quality Assurance Advisor The Concept of Quality in Clinical Research Dorota Śwituła Senior Clinical Quality Assurance Advisor 1 Agenda What is quality? How we define quality in clinical research? The standard components of a Quality

More information

European Forum for Good Clinical Practice Audit Working Party

European Forum for Good Clinical Practice Audit Working Party European Forum for Good Clinical Practice Audit Working Party REVISION OF THE ENGAGE 1 AUDITING GUIDELINE. AN OPTIONAL GUIDELINE FOR GCP COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS AUDITING This document

More information

ENTERPRISE RISK MANAGEMENT FRAMEWORK

ENTERPRISE RISK MANAGEMENT FRAMEWORK ENTERPRISE RISK MANAGEMENT FRAMEWORK COVENANT HEALTH LEGAL & RISK MANAGEMENT CONTENTS 1.0 PURPOSE OF THE DOCUMENT... 3 2.0 INTRODUCTION AND OVERVIEW... 4 3.0 GOVERNANCE STRUCTURE AND ACCOUNTABILITY...

More information

Essentials of RESEARCH GOVERNANCE

Essentials of RESEARCH GOVERNANCE Promoting Good Practice in Research Essentials of RESEARCH GOVERNANCE Information for Researchers, Students and Support Staff involved in Health & Social Care Research 2005 Reproduced with the permission

More information

New Investigator Collaborations and Interactions: Regulatory

New Investigator Collaborations and Interactions: Regulatory Your Health and Safety... Our priority Votre santé et votre Securité notre priorité New Investigator Collaborations and Interactions: Regulatory NCIC Clinical Trials Group New Investigator Clinical Trials

More information

How Industry Can Partner with FDA in Defining a Risk- Based Monitoring Program

How Industry Can Partner with FDA in Defining a Risk- Based Monitoring Program How Industry Can Partner with FDA in Defining a Risk- Based Monitoring Program Presenter: Jan Holladay Pierre, MPH Quality Principal Leader DynPort Vaccine Company LLC, A CSC Company This presentation

More information

What is necessary to provide good clinical data for a clinical trial?

What is necessary to provide good clinical data for a clinical trial? What is necessary to provide good clinical data for a clinical trial? Alain Barrois, Assistant Clinical Trials Operations Manager #EBMT2015 www.ebmt.org Is this a (typical) clinical trial? 2 Agenda Introduction

More information

and Regulatory Aspects

and Regulatory Aspects Good Clinical Practice and Regulatory Aspects Nora Espiritu MD, MPh, PhD (c) Former Executive Director of Research and Technology Transfer. Peruvian National Institute t of Health. Member of the Ethics

More information

QUALITY RISK MANAGEMENT (QRM): A REVIEW

QUALITY RISK MANAGEMENT (QRM): A REVIEW Lotlikar et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), 149-154 149 Available online at http://jddtonline.info REVIEW ARTICLE QUALITY RISK MANAGEMENT (QRM): A REVIEW Lotlikar MV Head Corporate

More information

Effective Internal Audit in the Financial Services Sector

Effective Internal Audit in the Financial Services Sector Effective Internal Audit in the Financial Services Sector Recommendations from the Committee on Internal Audit Guidance for Financial Services: How They Relate to the Global Institute of Internal Auditors

More information

Monitoring Clinical Trials with a SAS Risk-Based Approach

Monitoring Clinical Trials with a SAS Risk-Based Approach Paper DH05 Monitoring Clinical Trials with a SAS Risk-Based Approach Laurie Rose, SAS, Cary, NC USA ABSTRACT With global regulatory encouragement, the life sciences industry is gaining momentum to embrace

More information

Patient Centric Monitoring Methodology

Patient Centric Monitoring Methodology Patient Centric Monitoring Methodology The ICON approach to risk based monitoring in clinical trials An ICON White Paper Introduction The pharmaceutical and CRO industries are undergoing a radical shift

More information

Managing Clinical Operations Risks. Lars Schmiedeberg

Managing Clinical Operations Risks. Lars Schmiedeberg Managing Clinical Operations Risks Lars Schmiedeberg Disclaimer The views and opinion expressed in this slides are that of the presenter and do not necessarily reflect the views and opinions of ii4sm ltd.

More information

Later-Stage Development: Ensuring Compliance During. for a Competitive Advantage Webinar Series

Later-Stage Development: Ensuring Compliance During. for a Competitive Advantage Webinar Series Part II: Later-Stage Development: Ensuring Compliance During Clinical i l Trials Process Driven Compliance for a Competitive Advantage Webinar Series 29 September 2010 Process Driven Compliance Webinar

More information

DHHS/NIH/OD/OIR/OHSRP 1/2/2015

DHHS/NIH/OD/OIR/OHSRP 1/2/2015 DHHS/NIH/OD/OIR/OHSRP 1/2/2015 The audience for this course is Principal Investigators (PIs), investigators and Research Coordinators (RCs) serving on the study team of human clinical studies and trials.

More information

INTERIM SITE MONITORING PROCEDURE

INTERIM SITE MONITORING PROCEDURE INTERIM SITE MONITORING PROCEDURE 1. PURPOSE The purpose of this SOP is to describe the interim monitoring procedures conducted at Institution, according to GCP and other applicable local regulations.

More information

Regulator s Role in GCP

Regulator s Role in GCP Regulator s Role in GCP David A. Lepay, M.D., Ph.D. APEC GCP Inspection Workshop May 27, 2008 Objectives of this Talk Review the roles and responsibilities of the regulatory authority under GCP Identify

More information

REDUCING THE RISKS INHERENT IN EMERGENCY MEDICAL CONTACT AND UNBLINDING

REDUCING THE RISKS INHERENT IN EMERGENCY MEDICAL CONTACT AND UNBLINDING white paper REDUCING THE RISKS INHERENT IN EMERGENCY MEDICAL CONTACT AND UNBLINDING All sides agree that patient safety is paramount in the conduct of clinical trials. While focused on patient safety,

More information

Section 1 Project Management, Project Communication/Process Design, Mgmt, Documentation, Definition & Scope /CRO-Sponsor Partnership

Section 1 Project Management, Project Communication/Process Design, Mgmt, Documentation, Definition & Scope /CRO-Sponsor Partnership Section 1 Project Management, Project Communication/Process Design, Mgmt, Documentation, Definition & Scope /CRO-Sponsor Partnership PROJECT MANAGEMENT - SCOPE DEFINITION AND MANAGEMENT Understands the

More information

Centralized vs Onsite Monitoring:

Centralized vs Onsite Monitoring: Centralized vs Onsite Monitoring: A Sponsor s Balancing Act Applying a Risk-based Approach Introduction Since the August 2011 release of the draft guidance document by FDA on a risk-based approach to monitoring

More information

Introduction 2. 1. The Role of Pharmacy Within a NHS Trust 3. 2. Pharmacy Staff 4. 3. Pharmacy Facilities 5. 4. Pharmacy and Resources 6

Introduction 2. 1. The Role of Pharmacy Within a NHS Trust 3. 2. Pharmacy Staff 4. 3. Pharmacy Facilities 5. 4. Pharmacy and Resources 6 Index Index Section Page Introduction 2 1. The Role of Pharmacy Within a NHS Trust 3 2. Pharmacy Staff 4 3. Pharmacy Facilities 5 4. Pharmacy and Resources 6 5. Prescription Charges 7 6. Communication

More information

Guide to the National Safety and Quality Health Service Standards for health service organisation boards

Guide to the National Safety and Quality Health Service Standards for health service organisation boards Guide to the National Safety and Quality Health Service Standards for health service organisation boards April 2015 ISBN Print: 978-1-925224-10-8 Electronic: 978-1-925224-11-5 Suggested citation: Australian

More information

R&D Administration Manager. Research and Development. Research and Development

R&D Administration Manager. Research and Development. Research and Development Document Title: Document Number: Patient Recruitment SOP031 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D Administration Manager,

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 1 2 20 February 2012 EMA/541760/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration

More information

Role of IRB/IEC in GCP. Benjamin Kuo, MD, Dr.PH, CIP.

Role of IRB/IEC in GCP. Benjamin Kuo, MD, Dr.PH, CIP. Role of IRB/IEC in GCP Benjamin Kuo, MD, Dr.PH, CIP. Institutional Review Board (IRB) An independent body constituted of medical, scientific and non scientific members Responsible for ensuring protection

More information

How to Run Clinical Trials in Private Practice

How to Run Clinical Trials in Private Practice How to Run Clinical Trials in Private Practice Thomas M. Siler, MD Midwest Chest Consultants, PC Saint Charles, MO DISCLOSURE Dr. Siler has received research grants from GlaxoSmithKline, Forest, Boehringer

More information

CSR / Sustainability Governance and Management Assessment By Coro Strandberg Principal, Strandberg Consulting www.corostrandberg.

CSR / Sustainability Governance and Management Assessment By Coro Strandberg Principal, Strandberg Consulting www.corostrandberg. Introduction CSR / Sustainability Governance and Management Assessment By Coro Strandberg Principal, Strandberg Consulting www.corostrandberg.com June 2015 Companies which adopt CSR or sustainability 1

More information

Managing & Validating Research Data

Managing & Validating Research Data Research Management Standard Operating Procedure ISOP-H02 VERSION / REVISION: 2.0 EFFECTIVE DATE: 01 03 12 REVIEW DATE: 01 03 14 AUTHOR(S): CONTROLLER(S): APPROVED BY: Information Officer; NBT Clinical

More information

ICH Q10 Pharmaceutical Quality System (PQS)

ICH Q10 Pharmaceutical Quality System (PQS) ICH Q10 Pharmaceutical Quality System (PQS) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Q10 PQS Guideline Background Objectives

More information

Meeting Priorities of Biotech & Small Pharma Companies

Meeting Priorities of Biotech & Small Pharma Companies Meeting Priorities of Biotech & Small Pharma Companies Dr. Andreas Orfanos, MBBCH,FFPM,MBA Thrasos Therapeutics Inc. Vice President Clinical Research & Development 28 Oct 2015 Montreal Technoparc Private,

More information

R000. Revision Summary Revision Number Date Description of Revisions R000 Feb. 18, 2011 Initial issue of the document.

R000. Revision Summary Revision Number Date Description of Revisions R000 Feb. 18, 2011 Initial issue of the document. 2 of 34 Revision Summary Revision Number Date Description of Revisions Initial issue of the document. Table of Contents Item Description Page 1. Introduction and Purpose... 5 2. Project Management Approach...

More information

Core Training Outline

Core Training Outline Core Training Outline Modules: 1) Study Design 2) PI Oversight 3) Financial Management 4) Study Operations 5) Recruitment & Retention 6) Informed Consent 7) Investigational Products 8) Subject Safety 9)

More information

Annex 7 Guidelines for the preparation of a contract research organization master file

Annex 7 Guidelines for the preparation of a contract research organization master file World Health Organization WHO Technical Report Series, No. 957, 2010 Annex 7 Guidelines for the preparation of a contract research organization master file Background 1. General information 2. Quality

More information